Mydecine Innovations Group announced that it filed a patent application that would allow the company to create formulations utilizing nanoemulsion technology to enhance, stabilize and make repeatable properties of ingredients from traditional medicines.
Nanoemulsion is an advanced mode of drug delivery that has been developed to overcome the major drawbacks associated with conventional drug delivery systems.
The Denver, Colorado-based company said that this technology is critical to the company's active drug development as it provides increased control in delivery, which is an essential feature in microdosing and customizing dosages.
READ: Mydecine reports successful synthesis of novel tryptamine, improving the pharmaceutical properties of psilocin
“This patent filing marks a key milestone for Mydecine’s drug development pipeline in that we have introduced an additional wall of IP protection that covers important technologically innovative properties of compounds that can empower a number of over-the-counter supplements and consumer products,” said Josh Bartch, CEO of Mydecine.
He added: “As we continue to produce new methods to traditional medicinal roots, it is critical that we apply layerable patented technology to our discovery process in order to enhance the use of extracts and take advantage of increasing demand for these valuable compounds into today’s health treatments.”
The biotech company shared that the patent will cover formulations that are generally recognized as safe by the Food and Drugs Administration (GRAS-certified) and leverages increased bioavailability to enhance the properties available to consumers.
“These GRAS-pending nanotechnology formulations offer a significant opportunity to enhance the bioavailability of natural compounds found in traditional medicine, such as reishi and cordyceps, so that they can be added to an expanding variety of consumer products to achieve enhanced benefits,” said Rob Roscow, chief science officer of Mydecine.
He continued: “By fine-tuning our ingredients and extraction processes, we are able to deliver these valuable properties more accurately and effectively to consumers.”
Mydecine is focused on developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company, founded in 2020, is guided on a principle that there is a significant unmet need and lack of Innovations in the mental health and therapeutic treatment environments.
The wellness company is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders.
Contact Ritika at ritika@proactiveinvestors.com